[Clinical Significance of XPO1 High Expression in Diffuse Large B-Cell Lymphoma and Its Mechanism].

The expression of XPO1 in DLBCL patients was higher than that of the controls. Compared with XPO1 low-expression group, XPO1 high-expression group had a worse prognosis. The constructed risk model indicated that <i>XPO1</i> and 14 genes in nucleocytoplasmic transport pathway (NTP) might be potential prediction marker of adverse outcome in DLBCL. Moreover, KPT-8602 as well as the <i>XPO1</i> knockdown could inhibit cell proliferation, promote apoptosis, and induce cell cycle arrest in two DLBCL cell lines, Farage and SU-DHL-4. Based on the gene expression profiling in the datasets of DLBCL, patients were classified into <i>XPO1</i> high and <i>XPO1</i> low expression groups, and the <i>MYBL1</i> was identified as the down-stream effector of <i>XPO1</i>. Inhibiting the function of XPO1 or reducing its expression can significantly decrease the expression of <i>MYBL1</i> Conclusion: XPO1 is highly expressed in DLBCL, which is associated with poor prognosis. The oncogenic roles of the new <i>XPO1/MYBL1</i> signaling are identified in DLBCL and XPO1 inhibitor may be a potential option for newly-diagnosed DLBCL patients.